Citadel Advisors
PHAS

Citadel Advisors’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Citadel Advisors’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-11,000
Closed -$38K – 14758
2021
Q1 		$38K Buy
+11,000
New +$44.6K ﹤0.01% 12993

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PTP
Platform Technology Partners New York $519M AUM 20% 1-Year Est. Return

Citadel Advisors's PHAS Position: Q3 2022 in Review

Citadel Advisors sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q3 2022, closing a stake of 107,953 shares — an estimated $65K sold.

Citadel Advisors first reported a position in PHAS in Q2 2020 and held it in 8 quarters. The position peaked at $150K in Q2 2021. 38 funds tracked by Wall St. Rank hold PHAS as of Q3 2022.

  • Citadel Advisors reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Citadel Advisors sold 107,953 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q3 2022, an estimated $65K.
  • Citadel Advisors first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 8 quarters.
  • Citadel Advisors's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $150K in Q2 2021.
  • 38 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on Citadel Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.